First test of Rejection-Stopping pill for lung transplant patients
NCT ID NCT06948097
Summary
This early-stage study aims to check if a pill called fostamatinib is safe for lung transplant patients who develop harmful antibodies against their new lung. Thirty adult participants will take either the real drug or a placebo pill for eight weeks while continuing their standard care. Researchers will closely monitor for side effects and see if the drug shows any early signs of helping prevent organ rejection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Health System Foundation
Falls Church, Virginia, 22042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University School of Medicine
Stanford, California, 94305, United States
-
University of Utah Health
Salt Lake City, Utah, 84132, United States
Conditions
Explore the condition pages connected to this study.